caryophyllene and Neuralgia

caryophyllene has been researched along with Neuralgia* in 4 studies

Other Studies

4 other study(ies) available for caryophyllene and Neuralgia

ArticleYear
Anti-neuropathic Pain Mechanistic Study on
    CNS & neurological disorders drug targets, 2023, Volume: 22, Issue:6

    Neuropathic pain has become a contributor to the global burden of illness. However, the currently available drugs exhibit inadequate pain relief and significant side effects. Our previous study demonstrated that the essential oil of Ageratum conyzoides exerts potent antineuropathic pain activity through opioid receptor activation. Precocene II, longifolene, and caryophyllene are the largest component of the A. conyzoides essential oil.. The objective of the study was to determine the anti-neuropathic pain activity of precocene II, longifolene, and caryophyllene as single agents and in combination with pregabalin. Possible mechanisms of action involving the opioid receptor, ATP-sensitive potassium channel, and gammaaminobutyric acid (GABA) were further investigated.. The experimental animals (male mice Swiss Webster) were divided randomly into seven groups, namely, Normal control (naïve mice), Negative control (CMC 1%), Sham (CMC 1%), Positive control (Pregabalin 0,195 mg/ 20 g BW of mice), Test I (Precocene II 21.09 mg/Kg BW), Test II (Longifolene 9.94 mg/Kg BW), and Test III (Caryophyllene 3.64 mg/Kg BW). Each group contained 3 animals. The test groups that demonstrated anti-neuropathic pain activity were further tested in combination with pregabalin, followed by mechanistic studies. The negative, positive, and test I-III groups were induced with chronic constriction injury.. The results of the study demonstrated that caryophyllene and longifolene, but not precocene II, exerted anti-neuropathic pain activity. The caryophyllene was shown to involve in the activation of opioid receptors and ATP-sensitive potassium channels. It was also reported to increase GABA concentration in the spinal cord. We further found that longifolene exerted its action via opioid receptor activation. The combination of A. conyzoides essential oil, longifolene, or caryophyllene with pregabalin demonstrated additive anti-neuropathic pain activity.. Taken together, the results of the present study suggested that the A. conyzoides essential oil and caryophyllene have the potential to be developed as novel drugs to treat neuropathic pain.

    Topics: Animals; gamma-Aminobutyric Acid; Male; Mice; Neuralgia; Oils, Volatile; Pregabalin; Receptors, Opioid

2023
β-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain.
    Molecules (Basel, Switzerland), 2019, Dec-27, Volume: 25, Issue:1

    Topics: Animals; Brain; Disease Models, Animal; Female; Humans; Hyperalgesia; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Neuralgia; Polycyclic Sesquiterpenes; Receptor, Cannabinoid, CB2; Reverse Transcriptase Inhibitors; Skin; Zalcitabine

2019
Antiallodynic effect of β-caryophyllene on paclitaxel-induced peripheral neuropathy in mice.
    Neuropharmacology, 2017, Volume: 125

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Cannabinoid Receptor Modulators; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Indoles; Male; Neuralgia; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Piperidines; Polycyclic Sesquiterpenes; Pyrazoles; Random Allocation; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Sesquiterpenes; Spinal Cord

2017
The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:4

    The widespread plant volatile beta-caryophyllene (BCP) was recently identified as a natural selective agonist of the peripherally expressed cannabinoid receptor 2 (CB₂). It is found in relatively high concentrations in many spices and food plants. A number of studies have shown that CB₂ is critically involved in the modulation of inflammatory and neuropathic pain responses. In this study, we have investigated the analgesic effects of BCP in animal models of inflammatory and neuropathic pain. We demonstrate that orally administered BCP reduced inflammatory (late phase) pain responses in the formalin test in a CB₂ receptor-dependent manner, while it had no effect on acute (early phase) responses. In a neuropathic pain model the chronic oral administration of BCP attenuated thermal hyperalgesia and mechanical allodynia, and reduced spinal neuroinflammation. Importantly, we found no signs of tolerance to the anti-hyperalgesic effects of BCP after prolonged treatment. Oral BCP was more effective than the subcutaneously injected synthetic CB₂ agonist JWH-133. Thus, the natural plant product BCP may be highly effective in the treatment of long lasting, debilitating pain states. Our results have important implications for the role of dietary factors in the development and modulation of chronic pain conditions.

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Cannabinoid Receptor Agonists; Disease Models, Animal; Gene Expression Regulation; Hyperalgesia; Male; Mice; Mice, Congenic; Motor Activity; Nerve Tissue Proteins; Neuralgia; Neurons; Pain Measurement; Phytochemicals; Polycyclic Sesquiterpenes; Receptor, Cannabinoid, CB2; Sciatic Nerve; Sciatic Neuropathy; Sesquiterpenes; Spinal Cord

2014